Share this:
At the beginning of 2020, everyone in research and medicine who could pivot to focus on COVID-19 did. Scientists and physicians hauled out findings from previous epidemics. In papers and personal correspondence, they shared descriptions of the damage wrought by SARS-CoV-2. They started running potential drugs through their paces.
"When you have a completely new infection, and it's of epidemic and pandemic proportion, there is a lot of scrambling to figure out how to deal with it," says Zelalem Temesgen, M.D., a Mayo Clinic infectious diseases specialist.
At Mayo Clinic, it was a sort of controlled scramble. Cross-discipline relationships and a culture of collaboration are already part of the institution's fabric and that saved time. Years in one case. With a united science and medical infrastructure, Mayo Clinic researchers raced through the scientific steps to repurpose a cancer therapy into a clinical trial for COVID-19 treatment in less than a year.
Read the rest of the article on Discovery's Edge.
____________________________________________
Other Mayo Clinic medical research websites:
- Research at Mayo Clinic
- Discovery’s Edge
- Advancing the Science
- Forefront
- Mayo Clinic Center for Individualized Medicine
- Center for Regenerative Medicine
- Center for the Science of Health Care Delivery
Share this:
Related articles
National Influenza Vaccination Week will be observed Dec. 4–8, which makes this a good time to learn more about the flu and why it's especially important ...
When David Elder’s back started to hurt in the fall of 2022, he thought his recurrent spasms had returned. But when medication didn’t help like ...
When Joanina Gicobi began her Ph.D. degree five years ago at Mayo Clinic Graduate School of Biomedical Sciences, she was interested in thinking creatively about ways ...